A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

Start Date01 Jul 2025

Sponsor / Collaborator

AIM ImmunoTech, Inc.

[+1]

NCT04093323

/ RecruitingPhase 2IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

Start Date13 Nov 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT05756166

/ Active, not recruitingPhase 1/2IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

Start Date16 Feb 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Rintatolimod

100 Translational Medicine associated with Rintatolimod

100 Patents (Medical) associated with Rintatolimod

Literatures (Medical) associated with Rintatolimod

01 Nov 2024·Journal for ImmunoTherapy of Cancer

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer

Article

Author: Attwood, Kristopher ; Wang, Jianming ; Gnjatic, Sacha ; Ioannou, Giorgio ; De Souza, Igor ; Fitzpatrick, Victoria ; Kumar, Prasanna ; Miller, Janine ; Janes, Cayla ; Kalinski, Pawel ; Kokolus, Kathleen M ; Gandhi, Shipra ; Young, Jessica ; Opyrchal, Mateusz ; O'Connor, Tracey ; O’Connor, Tracey ; Roudko, Vladimir ; Slomba, Ronald T ; Levine, Ellis G ; Cortes Gomez, Eduardo ; Kalathil, Suresh ; Cappuccino, Helen ; Ozbey, Sinem ; Takabe, Kazuaki ; Edge, Stephen

Background:

Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30–40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.

Methods:

Phase I studyNCT04081389evaluated nine patients with early-stage TNBC who received 3 weeks of paclitaxel with CKM (dose-escalation of IFN-α2b), followed by 9 weeks of paclitaxel alone, dose-dense doxorubicin and cyclophosphamide, and surgery. Primary and secondary endpoints were safety and clinical efficacy, respectively.

Results:

The combination treatment was well-tolerated with no dose-limiting toxicities or irAEs. 5/9 patients achieved pCR and one patient had microinvasive disease (ypTmic). We observed elevated IFN signature and uniform decreases in CTL numbers (average 8.3-fold) in the blood of all treated patients. This was accompanied by reciprocal uniform increases in CD8β (overall 5.9-fold), CD8α/FoxP3 (2.11-fold), and CCL5 (4.73-fold) transcripts in TME, particularly pronounced in patients with pCR. Multiplex immunohistochemistry revealed selectively increased numbers of CTL (but not regulatory T cells) in both the epithelial and stromal tumor compartments and early decreases in the numbers of αSMA+vascular/stromal cells in the tumors of all pCR patients.

Conclusions:

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

15 Aug 2024·Clinical cancer research : an official journal of the American Association for Cancer Research

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Article

Author: van Eijck, Casper H.J. ; van Eijck, Casper W.F. ; Mustafa, Dana A.M. ; Aerts, Joachim G.J.V. ; Kucukcelebi, Songul ; Willemsen, Marcella ; Fellah, Amine ; Vadgama, Disha ; Haddaoui, Hassana el

Abstract:

Purpose::

Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.

Experimental Design::

Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.

Results::

Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.

Conclusions::

This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

01 Nov 2023·Journal for immunotherapy of cancer

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Article

Author: Kokolus, Kathleen M ; Wallace, Paul K ; Attwood, Kristopher ; Grimm, Melissa J ; Slomba, Ronald T ; Witkiewicz, Agnieszka ; O'Connor, Tracey L ; Minderman, Hans ; Williams, Lauren ; Groman, Adrienne ; Levine, Ellis G ; Kalinski, Pawel ; Soh, Kah Teong ; Early, Amy P ; Maguire, Orla ; Opyrchal, Mateusz ; Gandhi, Shipra ; Tarquini, Mary Lynne

Background:

Presence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts the effectiveness of cancer immunotherapies. The ability of toll-like receptor 3 (TLR3) ligands, interferons (IFNs) and COX2 inhibitors to synergistically induce CTL-attracting chemokines (but not regulatory T cell (Treg)-attractants) in the TME, but not in healthy tissues, observed in our preclinical studies, suggested that their systemic application can reprogram local TMEs.

Methods:

Six evaluable patients (33–69 years) with metastatic triple-negative breast cancer received six doses of systemic chemokine-modulating (CKM) regimen composed of TLR3 ligand (rintatolimod; 200 mg; intravenous), IFN-α2b (20 MU/m2; intravenous) and COX2 inhibitor (celecoxib; 2×200 mg; oral) over 2 weeks. The predetermined primary endpoint was the intratumoral change in the expression of CTL marker, CD8α, in the post-CKM versus pre-CKM tumor biopsies. Patients received follow-up pembrolizumab (200 mg, intravenously, every 3 weeks), starting 3–8 days after completion of CKM.

Results:

Post-CKM biopsies showed selectively increased CTL markers CD8α (average 10.2-fold, median 5.5-fold, p=0.034) and granzyme B (GZMB; 6.1-fold, median 5.8-fold, p=0.02), but not FOXP3 (Treg marker) relative to HPRT1 expression, resulting in the increases in average CD8α/FOXP3 ratio and GZMB/FOXP3 ratio. CKM increased intratumoral CTL-attractants CCL5 and CXCL10, but not Treg-attractants CCL22 or CXCL12. In contrast, CD8+T cells and their CXCR3+subset showed transient decreases in blood. One clinical response (breast tumor autoamputation) and three stable diseases were observed. The patient with clinical response remains disease free, with a follow-up of 46 months as of data cut-off.

Conclusions:

Short-term systemic CKM selectively increases CTL numbers and CTL/Treg ratios in the TME, while transiently decreasing CTL numbers in the blood. Transient effects of CKM suggest that its simultaneous application with checkpoint blockade and other forms of immunotherapy may be needed for optimal outcomes.

143

News (Medical) associated with Rintatolimod

08 May 2025

·www.globenewswire.com

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent Annual Meeting of the American Association of Immunologists held May 3-7, 2025, in Honolulu, HI. The paper, titled “Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of the TME,” discussed the unique two-level selectivity of action of Ampligen when used as a part of chemokine modulation and combined with PD-1 blockade or chemotherapy. Dr. Kalinski discussed the preclinical data and data from recently completed clinical trials showing the ability of Ampligen to selectively induce the desirable CTL-attracting chemokines, but not the counterproductive Treg-attracting chemokines, which differentiated it from poly-I:C. The second level of selectivity was the preferential activation of cancer tissues, rather than healthy tissues. The mechanistic data discussed by Dr. Kalinski indicate that the selectivity of Ampligen’s impact on the tumor microenvironment result from its avoidance of helicase-dependent activation of NFkB. This allows Ampligen to avoid the induction of TNFα and other NFkB-dependent undesirable inflammatory and suppressive factors, which are commonly induced by poly-I:C and other TLR ligands, and to focus its impact on the tumor tissues, which display elevated levels of endogenous NFkB. AIM CEO Thomas K. Equels commented: “These findings and Dr. Kalinski’s analysis further support our belief in the potential of Ampligen as a powerful therapeutic for unmet medical needs, including deadly cancers.” About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in oncology. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

ImmunotherapyAACRClinical Study

11 Mar 2025

·www.globenewswire.com

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its participation in the Virtual Investor “Top 5 for ‘25” On-Demand Conference. As part of the event, AIM CEO Thomas K. Equels presented his top five reasons why he believes the investment community and industry colleagues should pay attention to the Company in 2025: Progress in late-stage pancreatic cancer treatment with significant advancements in the Phase 1b/2 DURIPANC trial at Erasmus Medical Center in the Netherlands.Expanding research in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) research and post-COVID conditions, including the Company’s early recognition of the link between COVID-19 and ME/CFS-like conditions.Rapid advancement across oncology pipeline with multiple key trials reaching or approaching major milestones.Plans to advance Ampligen as a vaccine adjuvant for the growing and serious threat of bird flu as part of the Company’s antiviral priority development pipeline.Ampligen’s overall potential as a broad-spectrum immunotherapy. The on-demand video webcast available here and on the Events page in the Investors section of the Company’s website (aimimmuno.com). About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

ImmunotherapyVaccineClinical Study

11 Feb 2025

·www.globenewswire.com

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (“DURIPANC”)Watch the “What This Means” segment here OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM CEO Thomas K. Equels and Prof. Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at the Erasmus Medical Center (“Erasmus MC”) and Coordinating Investigator for the DURIPANC study in late-stage pancreatic cancer, participated in a Virtual Investor “What This Means” segment. Access the segment here.As part of the segment, Mr. Equels and Professor van Eijck discuss the recent approval from the Erasmus MC Safety Committee to proceed with the Phase 2 Study of Ampligen® and AstraZeneca’s Imfinzi as a potential combination treatment for late-stage pancreatic cancer. DURIPANC is an investigator-initiated, exploratory, open-label, single-center study in the Netherlands at Erasmus MC. The approval to proceed to Phase 2 was granted following the Safety Committee’s review of the complete Phase 1 safety data, which found the combination treatment to be generally well-tolerated with no treatment-related severe adverse events or dose-limiting toxicities.The Virtual Investor “What this Means” segment featuring AIM ImmunoTech is now available here.About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Investor Contact: JTC Team, LLCJenene Thomas908.824.0775AIM@jtcir.com

ImmunotherapyPhase 2IND

100 Deals associated with Rintatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D09661	Rintatolimod	L03A	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fatigue Syndrome, Chronic	Argentina	AIM ImmunoTech, Inc.	01 Jan 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Pancreatic Adenocarcinoma	Phase 2	United States	AIM ImmunoTech, Inc.	01 Jul 2025
Metastatic Pancreatic Cancer	Phase 2	Netherlands	AIM ImmunoTech, Inc.	09 Jan 2024
Metastatic Pancreatic Cancer	Phase 2	Netherlands	AstraZeneca PLC	09 Jan 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Netherlands	AstraZeneca PLC	09 Jan 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Netherlands	AIM ImmunoTech, Inc.	09 Jan 2024
Post Acute COVID 19 Syndrome	Phase 2	United States	AIM ImmunoTech, Inc.	30 Jun 2023
Colorectal Cancer	Phase 2	-	AIM ImmunoTech, Inc.	11 Apr 2022
COVID-19	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020
Hematologic Neoplasms	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020
Malignant Solid Neoplasm	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05592418 (AMP-518, CTgov)	Phase 2	Post Acute COVID 19 Syndrome	80	Rintatolimod (Ampligen / Rintatolimod)	olcbcwvssj(iqciwllcie) = ezkazvucfp xtzsvqhntm (qqxjxhpgay, 9.31) View more	-	22 Jan 2025
NCT05592418 (AMP-518, CTgov)	Phase 2	Post Acute COVID 19 Syndrome	80	Placebo / Normal Saline (Placebo / Saline)	olcbcwvssj(iqciwllcie) = vubekxuyqc xtzsvqhntm (qqxjxhpgay, 7.51) View more	-	22 Jan 2025
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Ampligen	apxnvlianv(qmkmtlawzq) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. yxvpkrgebl (xbjeokvlee ) View more	Positive	08 Feb 2024
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Placebo		Positive	08 Feb 2024
NCT03734692 (GlobeNewswire) Manual	Phase 2	Recurrent ovarian cancer	-	Ampligen+pembrolizumab	ikgtggjbyp(wegdiojerr) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors qljyvnhmay (palahraarf )	Positive	08 Nov 2023
NCT04081389 (Phase I study, CTgov)	Phase 1	Triple Negative Breast Cancer \| Early Stage Breast Carcinoma	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	tqokvgpwaq = bjzhiizago gtdqmuqmqc (vmzduensss, ofjljuuwpj - vjkjqpvuea) View more	-	11 Sep 2023
NCT04081389 (Phase I study, CTgov)	Phase 1		9	Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	tqokvgpwaq = nszsfukpkz gtdqmuqmqc (vmzduensss, naecrjwcce - gtqecxrslc) View more	-	11 Sep 2023
Corporate Publications Manual	Phase 1	-	40	Rintatolimod	yagzetesjr(jfcaeuystg) = utwqupmpkm dufimwszst (chqqwwzevi )	Positive	08 Dec 2022
Corporate Publications Manual	Phase 1	-	40	Placebo	yagzetesjr(jfcaeuystg) = lqxfudmlii dufimwszst (chqqwwzevi )	Positive	08 Dec 2022
NCT04081389 (SITC2022) Manual	Phase 1	Triple Negative Breast Cancer ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	nrbqocvewp(noykzqyxlw) = yruskloogg gxkzprfjva (asiezinzjb ) View more	Positive	01 Nov 2022
NCT00215813 (AMP-511, Biospace) Manual	Not Applicable	Post Acute COVID 19 Syndrome	4	Rintatolimod	zcjwxcptlz(wzdriotivw) = The preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen pdsuuarlop (wcxacrmopw )	Positive	28 Jul 2022
NCT03403634 (AACR2022) Manual	Phase 2	Colorectal Liver Metastases Microsatellite Stable (MSS)	12	celecoxib+IFNα2b IV+rintatolimod	hvhssnhqky(veeewkbwfu) = increased ctkfcacmar (gpfauvnqrk ) Met View more	Positive	15 Jun 2022
NCT03599453 (AACR2022)	Early Phase 1	Metastatic Triple-Negative Breast Carcinoma	6	Systemic rintatolimod and interferon-α2b	mzkwtxnszn(vgzpseptqg) = dfzjwdznic hyplrrsfzo (amosbdlons ) View more	-	15 Jun 2022
NCT03599453 (GlobeNewswire) Manual	Phase 1	Metastatic Triple-Negative Breast Carcinoma Triple Negative	6	IFN-2+Celecoxib+Ampligen+Pembrolizumab	irwinlvegu(dscbhnchml) = ptshryesoy mnyykqpolh (sdosckipnc ) View more	Positive	11 Apr 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis